PROGRESS
A major challenge in the study of neuropsychiatric disorders is to dissect and understand how the complex interactions between genes and environment are related to disease. A systematic approach to address these problems requires measuring differences at the level of DNA and RNA from large numbers of individuals who either do or do not manifest a clinical phenotype of interest. Due to the large size and diversity of the human genome, these are daunting tasks both in terms of labor and expense. Hybridization-based analysis using miniaturized complex arrays of nucleic acid components (DNA chips) are a new technology being developed to address these issues in a rapid and costeffective manner. The authors focus on reviewing current applications for DNA chip-based technology to problems of medical genetics and speculate about their future uses in clinical psychiatry. The ␤-amlyoid peptide (A␤) is thought to cause the neurodegeneration underlying Alzheimer's disease. Interestingly, A␤ is normally made by many of the cells in our body, but its function is unknown. The authors have investigated the effects of A␤ on platelet function and have found that low levels of A␤ (0.1-1 nM), similar to that in blood, augment platelet aggregation up to 2-fold. They also examined the activity of mutant A␤ peptides, corresponding with the APP 692 A → G and APP 693 E → Q which are found in familial Alzheimer's disease and hereditary cerebral hemorrhagic amyloidosis, Dutch type, and found that these peptides showed little to no activity. The inability of the Dutch A␤ peptide to augment platelet aggregation could account for the hemorrhagic pathology associated with the illness. The results of this study suggest that A␤ interacts with platelets in a highly specific manner and may play a role in regulating platelet function.
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Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine E Smeraldi, R Zanardi, F Benedetti, D Di Bella, J Perez, M Catalano
Depression has been shown to respond to antidepressant drugs which selectively inhibit the reuptake of the neurotransmitter serotonin (SSRIs). However, nonresponders to SSRIs are not uncommon, and reliable predictive criteria are yet lacking. The presence of a functional polymorphism within the promoter region of the serotonin transporter (5-HTT) gene, a prime target for SSRIs, prompted the authors to test the hypothesis of whether allelic variation of the 5-HTT promoter could be related to the antidepressant response to fluvoxamine and/or augmentation with pindolol (a serotonin autoreceptors antagonist) recently suggested for nonresponders. Both homozygotes and heterozygotes for the long variant of the 5-HTT promoter showed a better response to fluvoxamine than homozygotes for the short variant and these differences disappeared in the group treated with fluvoxamine plus pindolol. The authors conclude that fluvoxamine antidepressant efficacy seems to be related to allelic variation within the promoter of the 5-HTT gene. Thus, even without discarding the possible importance of other factors, genotyping the 5-HTT promoter may represent a promising tool to individualize the pharmacological treatment of depression.
Abnormal G protein ␣ s -and ␣ i2 -subunit mRNA expression in bipolar affective disorder O Spleiss, D van Calker, L Schä rer, K Adamovic, M Berger, PJ Gebicke-Haerter
Disturbances of events associated with intracellular signaling pathways have been hypothesized to be involved in the development or progression of affective disorders. Messenger RNA expression of three G-protein alpha-subunits, located at the beginning of these pathways, and p85 regulatory subunit of PI-3 kinase have been examined in patients with bipolar and unipolar affective disorder. Alpha s mRNA was markedly increased in bipolar patients, irrespective of lithium treatment. Alpha i2 mRNA was indistinguishable from unipolar patients, but was increased in bipolar patients by lithium. The data reveal elevated mRNA levels of G alpha s as a robust feature of bipolar affective disorder and a lithium-mediated increase of alpha i2 . The failure of feedback inhibition of alpha s by alpha i2 under lithium treatment supports the notion of major disturbances of the cAMP signaling system in bipolar illness. A large multiplex schizophrenia pedigree ascertained from Palau, Micronesia was genotyped with 406 highly polymorphic DNA markers evenly distributed throughout the genome. Assuming autosomal dominant inheritance with reduced penetrance, the highest genome-wide lod scores were found for DNA markers mapping to 2p13-14. Model free linkage analyses also implicated the 2p13-14 region. Of the 14 schizophrenia cases in this large extended family, eight share a haplotype spanning ෂ11 centimorgans. When 16 additional Palauan families were included in a followup study of this region, the linkage results remained positive. Overall, these data provided suggestive evidence for a chromosome 2p13-14 schizophrenia susceptibility locus in a subset of families in the Palauan population. Bipolar disorder is characterized by recurrent episodes of mania and depression. In two collaborative studies conducted in research centers in Canada, Austria, Czech Republic, Denmark, Germany and Sweden, the authors have investigated the genetic role of phospholipase C (PLC) in bipolar disorder. PLC is a key enzyme in the signalling system in nerve cells which is thought to be a target of action of lithium, an effective treatment for preventing recurrences of depression and mania. In the first study, they investigated 138 unrelated bipolar patients responsive to lithium and 163 control subjects and found that they differed in distribution of a genetic marker of the PLC gene. This result was consistent with findings of the second study which supported coinheritance of the marker and bipolar disorder in 32 families of patients successfully treated with lithium. These findings could provide a clue to the genetic nature of bipolar disorder and its treatment.
Direct determination of dopamine D
No evidence for involvement of the leptin gene in anorexia nervosa, bulimia nervosa, underweight or early onset extreme obesity: identification of two novel mutations in the coding sequence and a novel polymorphism in the leptin gene linked upstream region A Hinney, A Bornscheuer, M Depenbusch, B Mierke, A Tö lle, K Middeke, A Ziegler, H Roth, G Gerber, K Zamzow, A Ballauff, A Hamann, H Mayer, W Siegfried, G Lehmkuhl, F Poustka, MH Schmidt, H Hermann, BM Herpertz-Dahlmann, M Fichter, H Remschmidt, J Hebebrand Mutations in the leptin gene can result in profound obesity in both rodents and humans. The authors had previously argued that genes involved in weight regulation should be considered as candidate genes for AN. To investigate this hypothesis they screened the coding region of the leptin gene and part of the leptin gene linked upstream region (LEGLUR) in 49 patients with AN and 315 children and adolescents with extreme obesity. Two novel mutations in the coding region, each found in a single proband, and a novel polymorphism in the LEGLUR were identified. None of these are seemingly of functional relevance for the investi-gated phenotypes. In conclusion, an influence of variations in the leptin gene on AN or extreme early onset obesity was not detected. Anorexia nervosa is a disease characterized by decreased food intake and excessive weight loss. These symptoms are accompanied by abnormalities of many systems in the body, including amenorrhea. Leptin is a hormone secreted by fat cells which informs the brain about the amount of fat stores. Recent studies have implicated low leptin levels in playing an important role in bringing about the abnormalities that are observed in fasting. In contrast, increasing leptin levels are associated with the resumption of menses in anorexia nervosa. The present study confirms previous findings and indicates that leptin is a necessary factor for the resumption of menses in these patients. However, additional hormones such as estrogen and growth hormone also need to be fully normalized for the resumption of menses in anorexia nervosa.
Leptin in relation to
